STOCK TITAN

Emergent Biosolutions Inc - EBS STOCK NEWS

Welcome to our dedicated news page for Emergent Biosolutions (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Emergent Biosolutions's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Emergent Biosolutions's position in the market.

Rhea-AI Summary
Emergent BioSolutions Inc. has rescheduled its conference call to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023. The call will now take place on Wednesday, November 8, at 5:00 pm eastern time. Participants can access the call via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
acquisition earnings
-
Rhea-AI Summary
Emergent BioSolutions to host conference call to discuss Q3 2023 financial results and business developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
acquisition earnings
-
Rhea-AI Summary
Emergent partners with Emmitt Smith to raise awareness of opioid dangers and promote NARCAN® Nasal Spray
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
partnership acquisition
Rhea-AI Summary
Emergent BioSolutions announces appointment of Neal Fowler and Don DeGolyer to its Board of Directors, bringing extensive biopharmaceutical industry and sales experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
management acquisition
-
Rhea-AI Summary
Emergent ships NARCAN® Naloxone HCl Nasal Spray to stores and online retailers, priced at $44.99. It will be available nationwide in September. Access to NARCAN® Nasal Spray helps respond to opioid emergencies and save lives. Emergent has not raised the price since 2016 and has lowered the public interest price to $41.00. Almost 17 million doses of naloxone were distributed in the U.S. in 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.55%
Tags
acquisition
-
Rhea-AI Summary
Emergent BioSolutions reports Q2 2023 total revenues of $338M, net loss of $261M, and adjusted EBITDA of $56M. The company updates its FY 2023 guidance and provides an initial Q3 2023 forecast for total revenues. It also announces strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.78%
Tags
acquisition earnings
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) is refocusing its business on core products such as medical countermeasures and NARCAN Nasal Spray. This strategic shift will lead to cost savings of over $100 million annually and a reduction of approximately 400 employees. The company is also eliminating the COO role and is expecting to incur costs of approximately $19 million - $21 million in the third quarter of 2023. Emergent has recently achieved key strategic milestones, including securing contracts with the U.S. government and FDA approval for NARCAN Nasal Spray to be available over-the-counter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
acquisition
-
Rhea-AI Summary
Emergent BioSolutions Inc. has been awarded a 10-year contract by BARDA valued at up to $704 million for the development, manufacturing, and procurement of Ebanga™, a treatment for Ebola virus disease. The contract includes a base period of performance and option periods for advanced development and procurement over five years. Emergent will work on post-licensure commitments and technology transfer as part of manufacturing scale-up.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.97%
Tags
acquisition
-
Rhea-AI Summary
Emergent BioSolutions Inc. (NYSE: EBS) will hold a conference call on August 8, 2023, to discuss second-quarter financial results, recent business developments, revenue guidance for Q3 2023, and financial outlook for full year 2023. Participants can join via webcast or telephone, with a replay available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
acquisition earnings
Rhea-AI Summary
Emergent BioSolutions Inc. announced that the U.S. FDA has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis. The vaccine has been delivered to the U.S. Department of Health and Human Services since 2019 and will continue to be procured post-approval. CYFENDUS™ vaccine is a component of the U.S. government’s preparedness efforts against anthrax, a high-priority national security threat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
acquisition fda approval
Emergent Biosolutions Inc

NYSE:EBS

EBS Rankings

EBS Stock Data

135.21M
51.22M
2.89%
79.79%
11.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Gaithersburg

About EBS

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent